Successful therapeutic exploitation of BCR-ABL fusion in chronic myeloid leukemia (CML) by the small molecular inhibitor imatinib has become the paradigm of targeted therapy (Kantarjian et al., 2002). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.